Abstract
Various compound libraries of the Drug Therapeutic Program (DTP) of the NIH/NCI were screened against the catalytic subunit and the tetrameric holoenzyme of protein kinase CK2. Different IC50 values were obtained for the two CK2 molecules. In the case of nortangeretin, the IC50 value was 0.34 μM for the catalytic subunit and 15 μM for the holoenzyme. In the case of coumestrol, opposite results were obtained, i.e., high IC50 for the CK2α subunit (2.7 μM) and a lower IC50 value for the holoenzyme (0.19 μM).
From the many compounds identified to inhibit CK2, we have selected 14 different compounds and listed them according to their CK2α/CK2 holoenzyme IC50 ratio.
Four compounds were tested on a panel of seven cell lines revealing considerable differences in the degree of CK2 inhibition inside the cells.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Milner JA, Romagnolo DF (2010) Bioactive compounds and cancer. Springer, New York
Olsen LF, Issinger O-G, Guerra B (2013) The Yin and Yang of redox regulation. Redox Rep 18:245–252. doi:10.1179/1351000213Y.0000000059
Kumamoto T, Fujii M, Hou D-X (2009) Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem 332:33–41. doi:10.1007/s11010-009-0171-9
Walker EH, Pacold ME, Perisic O et al (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6:909–919
Lolli G, Cozza G, Mazzorana M et al (2012) Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry 51:6097–6107. doi:10.1021/bi300531c
Golub AG, Bdzhola VG, Kyshenia YV et al (2011) Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2. Mol Cell Biochem 356:107–115. doi:10.1007/s11010-011-0945-8
Boldyreff B, Rasmussen TL, Jensen HH et al (2008) Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay. J Biomol Screen 13:1035–1040. doi:10.1177/1087057108326079
Guerra B, Issinger O-G (2008) Protein kinase CK2 in human diseases. Curr Med Chem 15:1870–1886
Trembley JH, Chen Z, Unger G et al (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36:187–195. doi:10.1002/biof.96
St-Denis NA, Litchfield DW (2009) Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 66:1817–1829. doi:10.1007/s00018-009-9150-2
Filhol O, Cochet C (2009) Protein kinase CK2 in health and disease. Cell Mol Life Sci 66:1830–1839. doi:10.1007/s00018-009-9151-1
Olsen BB, Boldyreff B, Niefind K, Issinger O-G (2006) Purification and characterization of the CK2alpha'-based holoenzyme, an isozyme of CK2alpha: a comparative analysis. Protein Expr Purif 47:651–661. doi:10.1016/j.pep.2005.12.001
Yim H, Lee YH, Lee CH, Lee SK (1999) Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med 65:9–13. doi:10.1055/s-1999-13953
Janeczko M, Masłyk M, Szyszka R, Baier A (2011) Interactions between subunits of protein kinase CK2 and their protein substrates influences its sensitivity to specific inhibitors. Mol Cell Biochem 356:121–126. doi:10.1007/s11010-011-0951-x
Stalter G, Siemer S, Becht E et al (1994) Asymmetric Expression of Protein Kinase CK2 Subunits in Human Kidney Tumors. Biochem Biophys Res Commun 202:141–147. doi:10.1006/bbrc.1994.1904
Deshiere A, Duchemin-Pelletier E, Spreux E et al (2013) Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction. Oncogene 32:1373–1383. doi:10.1038/onc.2012.165
Cho S-Y, Cho S, Park E et al (2014) Coumestrol suppresses hypoxia inducible factor 1α by inhibiting ROS mediated sphingosine kinase 1 in hypoxic PC-3 prostate cancer cells. Bioorg Med Chem Lett 24:2560–2564. doi:10.1016/j.bmcl.2014.03.084
Liu S, Hsieh D, Yang Y-L et al (2013) Coumestrol from the national cancer Institute’s natural product library is a novel inhibitor of protein kinase CK2. BMC Pharmacol Toxicol 14:36. doi:10.1186/2050-6511-14-36
Lee Y-H, Yuk HJ, Park K-H, Bae Y-S (2013) Coumestrol induces senescence through protein kinase CKII inhibition-mediated reactive oxygen species production in human breast cancer and colon cancer cells. Food Chem 141:381–388. doi:10.1016/j.foodchem.2013.03.053
Hosoi Y, Matsumoto Y, Tomita M et al (2002) Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity. Br J Cancer 86:1143–1149. doi:10.1038/sj.bjc.6600191
Borges S, Döppler HR, Storz P (2014) A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. Breast Cancer Res Treat 144:79–91. doi:10.1007/s10549-014-2857-2
Sandholt IS, Olsen BB, Guerra B, Issinger O-G (2009) Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 20:238–248. doi:10.1097/CAD.0b013e328326472e
Klopffleisch K, Issinger O-G, Niefind K (2012) Low-density crystal packing of human protein kinase CK2 catalytic subunit in complex with resorufin or other ligands: a tool to study the unique hinge-region plasticity of the enzyme without packing bias. Acta Crystallogr D Biol Crystallogr 68:883–892. doi:10.1107/S0907444912016587
Battistutta R, Mazzorana M, Cendron L et al (2007) The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. Chembiochem 8:1804–1809. doi:10.1002/cbic.200700307
Speisky H, Cassels BK (1994) Boldo and boldine: an emerging case of natural drug development. Pharmacol Res 29:1–12
O’Brien P, Carrasco-Pozo C, Speisky H (2006) Boldine and its antioxidant or health-promoting properties. Chem Biol Interact 159:1–17. doi:10.1016/j.cbi.2005.09.002
Gerhardt D, Bertola G, Dietrich F et al (2014) Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β. Urol Oncol 32:36. doi:10.1016/j.urolonc.2013.02.012
Tamm I, Bablanian R, Nemes MM et al (1961) Relationship between structure of benzimidazole derivatives and selective virus inhibitory activity. Inhibition of poliovirus multiplication and cytopathic effects by 2-(alpha-hydroxybenzyl)-benzimidazole, and its 5-chloroderivative. J Exp Med 113:625–656
Manerba M, Vettraino M, Fiume L et al (2012) Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem 7:311–317. doi:10.1002/cmdc.201100471
Farabegoli F, Vettraino M, Manerba M et al (2012) Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci 47:729–738. doi:10.1016/j.ejps.2012.08.012
Vettraino M, Manerba M, Govoni M, Di Stefano G (2013) Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1. Anticancer Drugs 24:862–870. doi:10.1097/CAD.0b013e328363ae50
Zschoernig B, Mahlknecht U (2009) Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2. Biochem Biophys Res Commun 381:372–377. doi:10.1016/j.bbrc.2009.02.085
Kang H, Jung J-W, Kim MK, Chung JH (2009) CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 4:e6611. doi:10.1371/journal.pone.0006611
Dixit D, Sharma V, Ghosh S et al (2012) Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 3:e271. doi:10.1038/cddis.2012.10
Correché ER, Enriz RD, Piovano M et al (2004) Cytotoxic and apoptotic effects on hepatocytes of secondary metabolites obtained from lichens. Altern Lab Anim 32:605–615
Wassman CD, Baronio R, Demir Ö et al (2013) Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 4:1407. doi:10.1038/ncomms2361
Lohézic-Le Dévéhat F, Tomasi S, Elix JA et al (2007) Stictic acid derivatives from the lichen Usnea articulata and their antioxidant activities. J Nat Prod 70:1218–1220. doi:10.1021/np070145k
Pal HC, Sharma S, Strickland LR et al (2014) Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways. PLoS One 9:e86338. doi:10.1371/journal.pone.0086338
Syed DN, Adhami VM, Khan MI, Mukhtar H (2013) Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem 13:995–1001
Adhami VM, Syed DN, Khan N, Mukhtar H (2012) Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 84:1277–1281. doi:10.1016/j.bcp.2012.07.012
Currais A, Chiruta C, Goujon-Svrzic M et al (2014) Screening and identification of neuroprotective compounds relevant to Alzheimer’s disease from medicinal plants of S. Tomé e Príncipe. J Ethnopharmacol. doi:10.1016/j.jep.2014.06.046
Jang KY, Jeong S-J, Kim S-H et al (2012) Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells. Cancer Lett 319:197–202. doi:10.1016/j.canlet.2012.01.008
Jung CH, Kim H, Ahn J et al (2013) Fisetin regulates obesity by targeting mTORC1 signaling. J Nutr Biochem 24:1547–1554. doi:10.1016/j.jnutbio.2013.01.003
Karioti A, Bilia AR (2010) Hypericins as potential leads for new therapeutics. Int J Mol Sci 11:562–594. doi:10.3390/ijms11020562
Gronquist M, Bezzerides A, Attygalle A et al (2001) Attractive and defensive functions of the ultraviolet pigments of a flower (Hypericum calycinum). Proc Natl Acad Sci U S A 98:13745–13750. doi:10.1073/pnas.231471698
Krammer B, Verwanger T (2012) Molecular response to hypericin-induced photodamage. Curr Med Chem 19:793–798
Jocham D, Stepp H, Waidelich R (2008) Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 53:1138–1148. doi:10.1016/j.eururo.2007.11.048
Amin A, Gali-Muhtasib H, Ocker M, Schneider-Stock R (2009) Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci 5:1–11
Hošek J, Toniolo A, Neuwirth O, Bolego C (2013) Prenylated and geranylated flavonoids increase production of reactive oxygen species in mouse macrophages but inhibit the inflammatory response. J Nat Prod 76:1586–1591. doi:10.1021/np400242e
Yang R, Hanwell H, Zhang J et al (2011) Antiproliferative activity of pomiferin in normal (MCF-10A) and transformed (MCF-7) breast epithelial cells. J Agric Food Chem 59:13328–13336. doi:10.1021/jf202898g
Son IH, Chung I-M, Lee SI et al (2007) Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett 17:4753–4755. doi:10.1016/j.bmcl.2007.06.060
Bajer MM, Kunze MM, Blees JS et al (2014) Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor. Biochem Pharmacol 88:313–321. doi:10.1016/j.bcp.2014.01.034
Grace MH, Wilsonb GR, Kandil FE et al (2009) Characteristic flavonoids from Acacia burkittii and A. acuminata heartwoods and their differential cytotoxicity to normal and leukemia cells. Nat Prod Commun 4:69–76
Rezaei-Sadabady R, Eidi A, Zarghami N, Barzegar A (2014) Intracellular ROS protection efficiency and free radical-scavenging activity of quercetin and quercetin-encapsulated liposomes. Artif Cells Nanomed Biotechnol 1–7. doi: 10.3109/21691401.2014.926456
Rockenbach L, Bavaresco L, Fernandes Farias P et al (2013) Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells. Urol Oncol 31:1204–1211. doi:10.1016/j.urolonc.2011.10.009
Kim Y, Kim W-J, Cha E-J (2011) Quercetin-induced growth inhibition in human bladder cancer cells is associated with an increase in Ca-activated K channels. Korean J Physiol Pharmacol 15:279–283. doi:10.4196/kjpp.2011.15.5.279
Sak K (2014) Site-specific anticancer effects of dietary flavonoid quercetin. Nutr Cancer 66:177–193. doi:10.1080/01635581.2014.864418
Men K, Duan X, Wei XW et al (2014) Nanoparticle-delivered quercetin for cancer therapy. Anticancer Agents Med Chem 14:826–832
Niefind K, Guerra B, Ermakowa I, Issinger O-G (2001) Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J 20:5320–5331. doi:10.1093/emboj/20.19.5320
Boldyreff B, Meggio F, Pinna LA, Issinger O-G (1994) Efficient autophosphorylation and phosphorylation of the beta-subunit by casein kinase-2 require the integrity of an acidic cluster 50 residues downstream from the phosphoacceptor site. J Biol Chem 269:4827–4831
Boldyreff B, Meggio F, Pinna LA, Issinger O-G (1994) Protein kinase CK2 structure-function relationship: effects of the beta subunit on reconstitution and activity. Cell Mol Biol Res 40:391–399
Meggio F, Boldyreff B, Issinger O-G, Pinna LA (1994) Casein kinase 2 down-regulation and activation by polybasic peptides are mediated by acidic residues in the 55-64 region of the beta-subunit. A study with calmodulin as phosphorylatable substrate. Biochemistry 33:4336–4342
Raaf J, Brunstein E, Issinger O-G, Niefind K (2008) The interaction of CK2alpha and CK2beta, the subunits of protein kinase CK2, requires CK2beta in a preformed conformation and is enthalpically driven. Protein Sci 17:2180–2186. doi:10.1110/ps.037770.108
Raaf J, Brunstein E, Issinger O-G, Niefind K (2008) The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol 15:111–117. doi:10.1016/j.chembiol.2007.12.012
Raaf J, Issinger O-G, Niefind K (2008) Insights from soft X-rays: the chlorine and sulfur sub-structures of a CK2alpha/DRB complex. Mol Cell Biochem 316:15–23. doi:10.1007/s11010-008-9826-1
Olsen BB, Fischer U, Rasmussen TL et al (2011) Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α' levels. Mol Cell Biochem 356:139–147. doi:10.1007/s11010-011-0954-7
Olsen BB, Guerra B (2008) Ability of CK2beta to selectively regulate cellular protein kinases. Mol Cell Biochem 316:115–126. doi:10.1007/s11010-008-9817-2
Skjøth IHE, Issinger O-G (2006) Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 28:217–229
Yde CW, Gyrd-Hansen M, Lykkesfeldt AE et al (2007) Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 6:1869–1876. doi:10.1158/1535-7163.MCT-07-0072
Acknowledgments
We thank the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, USA, for providing us with plated and vialed samples from the various compound sets. The advice of Dr. David Newman at the start of the investigation is particularly acknowledged. We also thank the many students who have been involved in some of the screenings presented in this report. This work was supported in part by Grosserer M. Brogaard og Hustrus Mindefond and the Danish Council for Independent Research-Natural Sciences (grant 1323-00212A to B. Guerra), the Danish Cancer Society (grant 252-1109-210), and the Danish Research Council (grant 21-04-0517) to O.-G. Issinger.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rasmussen, T.D., Guerra, B., Issinger, OG. (2015). Screening of DTP Compound Libraries for CK2 Inhibitors with Focus on Natural Products. In: Ahmed, K., Issinger, OG., Szyszka, R. (eds) Protein Kinase CK2 Cellular Function in Normal and Disease States. Advances in Biochemistry in Health and Disease, vol 12. Springer, Cham. https://doi.org/10.1007/978-3-319-14544-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-14544-0_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14543-3
Online ISBN: 978-3-319-14544-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)